Use of TDF in Patients With Inactive Chronic Hepatitis B Infection
Status:
Active, not recruiting
Trial end date:
2023-01-01
Target enrollment:
Participant gender:
Summary
Recent evidence suggests that patients with inactive chronic hepatitis B (CHB) may develop
the same types of liver complications that patients in the active state of hepatitis B virus
(HBV) infection experience. Treatment guidelines for patients in the active state of HBV
infection indicate that HBsAg clearance is associated with definitive remission of the
activity of chronic HBV & improved long-term outcome. Clinical data showed that HBsAg
clearance is achievable, in a small population of patients on continuous treatment with
potent oral antivirals (OAVs), such as tenofovir disoproxil fumarate (TDF). It is possible
the same OAVs can have the same effect in patients with inactive CHB, but in a shorter
treatment duration. The purpose of this study is to find out if TDF is effective in
controlling HBV DNA & promoting seroconversion from HBsAg-positive to HBsAb-positive in
patients with inactive CHB.